In 20-40% of human breast cancers the erbB-2 or neu gene is amplified leading to mRNA and protein overexpression. This overexpression is likely to be involved in either the initiation or progression of these tumor cells. Amplification of the erbB-2 gene has been linked to a poorer prognosis. In phase I, we propose to generate monoclonal and polyclonal antibodies to extracellular as well as intracellular regions of the erbB- 2 protein. We will prepare antigen from two sources: mouse fibroblasts expressing large amounts of the human erbB-2 protein and bacteria genetically engineered to express specific regions of the erbB-2 protein. The resulting antibody preparations will be tested for their ability to specifically recognize human erbB-2 protein. In phase II, we will explore the uses of these antibodies in diagnosis and therapy of breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA050077-01
Application #
3492317
Study Section
(SSS)
Project Start
1989-06-01
Project End
1989-11-30
Budget Start
1989-06-01
Budget End
1989-11-30
Support Year
1
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Molecular Oncology, Inc.
Department
Type
DUNS #
City
Gaithersburg
State
MD
Country
United States
Zip Code
20878